Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by Swiss National Bank

Swiss National Bank increased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) by 1.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,400 shares of the company’s stock after buying an additional 800 shares during the quarter. Swiss National Bank owned about 0.17% of Krystal Biotech worth $3,438,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its stake in Krystal Biotech by 4.1% during the 1st quarter. Bank of New York Mellon Corp now owns 86,895 shares of the company’s stock valued at $5,782,000 after purchasing an additional 3,444 shares in the last quarter. MetLife Investment Management LLC boosted its stake in Krystal Biotech by 54.4% during the 1st quarter. MetLife Investment Management LLC now owns 10,266 shares of the company’s stock valued at $683,000 after purchasing an additional 3,618 shares in the last quarter. Rhumbline Advisers boosted its stake in Krystal Biotech by 10.0% during the 1st quarter. Rhumbline Advisers now owns 23,839 shares of the company’s stock valued at $1,586,000 after purchasing an additional 2,172 shares in the last quarter. BlackRock Inc. boosted its stake in Krystal Biotech by 4.9% during the 1st quarter. BlackRock Inc. now owns 1,683,511 shares of the company’s stock valued at $112,020,000 after purchasing an additional 78,015 shares in the last quarter. Finally, Great West Life Assurance Co. Can boosted its stake in Krystal Biotech by 51.9% during the 1st quarter. Great West Life Assurance Co. Can now owns 1,013 shares of the company’s stock valued at $72,000 after purchasing an additional 346 shares in the last quarter. 80.80% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Daniel Janney sold 7,900 shares of the stock in a transaction on Wednesday, April 19th. The stock was sold at an average price of $90.32, for a total transaction of $713,528.00. Following the completion of the sale, the director now directly owns 224,462 shares in the company, valued at $20,273,407.84. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Krystal Biotech news, Director Dino A. Rossi sold 40,000 shares of the stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $83.25, for a total transaction of $3,330,000.00. Following the transaction, the director now directly owns 83,691 shares of the company’s stock, valued at $6,967,275.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel Janney sold 7,900 shares of the firm’s stock in a transaction dated Wednesday, April 19th. The shares were sold at an average price of $90.32, for a total value of $713,528.00. Following the completion of the sale, the director now directly owns 224,462 shares in the company, valued at $20,273,407.84. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 90,000 shares of company stock worth $7,786,432. Corporate insiders own 17.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on KRYS. The Goldman Sachs Group raised Krystal Biotech from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $79.00 to $124.00 in a research note on Tuesday, February 28th. Guggenheim reissued a “buy” rating and set a $101.00 price objective on shares of Krystal Biotech in a research note on Tuesday, February 28th. Stifel Nicolaus began coverage on Krystal Biotech in a research note on Monday, April 17th. They set a “buy” rating and a $102.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $119.00 price objective on shares of Krystal Biotech in a research note on Tuesday, February 28th. Finally, Bank of America raised their price objective on Krystal Biotech from $105.00 to $118.00 in a research note on Sunday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $116.17.

Krystal Biotech Stock Up 9.8 %

KRYS opened at $96.06 on Monday. The stock has a fifty day moving average of $83.20 and a 200-day moving average of $79.86. The firm has a market capitalization of $2.48 billion, a P/E ratio of -18.19 and a beta of 0.85. Krystal Biotech, Inc. has a 12-month low of $49.17 and a 12-month high of $97.31.

Krystal Biotech (NASDAQ:KRYS – Get Rating) last released its earnings results on Monday, February 27th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.01. On average, analysts expect that Krystal Biotech, Inc. will post -5.85 earnings per share for the current fiscal year.

About Krystal Biotech

(Get Rating)

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization.